News

Plus, Company Comments on Its Poster at Prestigious American Glaucoma Society Meeting SAN DIEGO--(BUSINESS WIRE) (March 15th, 2022) --Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces the initial closing of a Series A

Plus, Company Advances Plans for Phase 2b Trial in 2022 January 19th, 2022 SAN DIEGO--(BUSINESS WIRE)--Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the acceptance and presentation of a poster highlighting its latest clinical

Plus, Company Receives Patent for Novel Post-Cataract Surgery Lens SAN DIEGO--(BUSINESS WIRE)--Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces enlightening findings from its primary market research with optometrists and ophthalmologists related to contact lens

The Coming Rise of Drug-delivery Contact Lenses This novel new system could mark a significant advancement for eye care. By Melissa Barnett, OD The use of contact lenses as ocular drug delivery systems was first introduced as an idea decades ago. As contact lenses have

Plus, Company Spotlights its Successful First-in-human Clinical Study Results at Premier Eye Care and Investor Conferences SAN DIEGO, CA, USA (Business Wire, June 8th, 2021) – Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight,

First-in-human Trial with Novel Glaucoma Treatment Confirmed Favorable Safety Profile and Signaled Efficacy SAN DIEGO, CA, USA (March 16th, 2021) – Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the successful completion of the first